Українська Abstract
Acne vulgaris (AV) is a chronic, inflammatory skin disease affecting 80% of young adults and adolescents, causing lesions, scarring, and pigmentation in the pilosebaceous unit. Managing AV effectively crucial to improving patients’ quality of life and preventing long-term dermatological complications. This study aimed to evaluate the efficacy of three widely used topical treatments for AV, which are: benzoyl peroxide, retinoid, and salicylic acid treatments, in managing mild to moderate acne using a cross-sectional observational study design. The study analysed the effectiveness of benzoyl peroxide, retinoid, and salicylic acid treatments for mild to moderate acne over an 8-week period. Participants aged 15 to 50 were randomly assigned to three treatment groups and outcomes were measured through physical exams and questionnaires. The variables assessed included lesion count, acne severity using GAGS scores, scarring, and skin texture and the data was analysed using SPSS, paired T-tests, and ANOVA to identify the most effective treatment. The study found that benzoyl peroxide significantly improved skin texture and eliminated severe inflammatory cases. Retinoids showed the most reduction in non-inflammatory and inflammatory lesions, with 55% of participants showing only mild lesions post-treatment. Retinoids also reduced severe acne scarring and improved skin texture. Salicylic acid produced moderate improvements, reducing non-inflammatory lesions and improving skin texture. Benzoyl peroxide and retinoids significantly improved skin texture, however, benzoyl peroxide showed mixed results in scarring. Paired sample t-tests confirmed significant improvements in skin texture and non-inflammatory lesions for both benzoyl peroxide and retinoid groups. The findings revealed that retinoids are more effective for non-inflammatory acne lesions and benzoyl peroxide for severe inflammatory cases, allowing for personalised treatment plans. This approach offers valuable insights for improving acne management outcomes. The study can help dermatologists in selecting effective treatments for acne based on lesion type and severity
Keywords:
[1] Lueangarun S, Sriviriyakul K, Tempark T, Managit C, Sithisarn P. Clinical efficacy of 0.5% topical mangosteen extract in nanoparticle-loaded gel in treatment of mild-to-moderate acne vulgaris: A 12-week, split-face, double-blinded, randomized, controlled trial. J Cosmet Dermatol. 2019;18(5):1395–1403. DOI: 10.1111/jocd.12856
[2] Bhatt S, Kothari R, Tripathy DM, Sandhu S, Babaei M, Goldust M. Emerging drugs for the treatment of acne: A review of phase 2 & 3 trials. Expert Opin Emerg Drugs. 2022;27(3):241–51. DOI: 10.1080/14728214.2022.2110239
[3] Zhang T, Sun B, Guo J, Wang M, Cui H, Mao H, et al. Active pharmaceutical ingredient poly(ionic liquid)based microneedles for the treatment of skin acne infection. Acta Biomater. 2020;115:136–47. DOI: 0.1016/j. actbio.2020.08.023
[4] Ye CX, Yi J, Su Z, Gao X, Jiang X, Yu N, et al. 2% supramolecular salicylic acid hydrogel vs. adapalene gel in mild to moderate acne vulgaris treatment: A multicenter, randomized, evaluator-blind, parallel-controlled trial. J Cosmet Dermatol. 2024;23(6):2125–34. DOI: 10.1111/jocd.16238
[5] Gern A, Xu S, Walter J, Vakharia P. A randomized controlled double-blinded split-face prospective clinical study to assess the efficacy, safety, and tolerability of a novel 3-step routine compared to benzyl peroxide for the treatment of mild to moderate acne vulgaris. Arch Dermatol Res. 2024;316:230. DOI: 10.1007/s00403-024-02874-9
[6] Chen W, Dai R, Li L. The prevalence of self-declared sensitive skin: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(8):1779–88. DOI: 10.1111/jdv.16166
[7] Dikicier BS. Topical treatment of acne vulgaris: Efficiency, side effects, and adherence rate. J Int Med Res. 2019;47(7):2987–92. DOI: 10.1177/0300060519847367
[8] Jorgaqi E, Savo I, Koraqi A, Doci X, Cela R, Vasili E, et al. Efficacy of acne vulgaris treatment protocols according to its clinical forms. Dermatol Ther. 2020;33(4):e1361. DOI: 10.1111/dth.13611
[9] Sarkar R, Ghunawat S, Garg VK. Comparative study of 35% Glycolic acid, 20% Salicylic-10% Mandelic acid, and Phytic acid combination peels in the treatment of active Acne and postacne pigmentation. J Cutan Aesthet Surg. 2019;12(3):158–63. DOI: 10.4103/JCAS.JCAS_135_18
[10] Sattar K, Sakina S, Mumtaz S, Behram F, Akbar A, Jadoon SK, et al. Safety and efficacy of fixed-dose combination of adapalene and benzoyl peroxide in acne vulgaris treatment: A systematic review of clinical trials. Cureus. 2024;16(9):e69341. DOI: 10.7759/cureus.69341
[11] Bhadra P. A literature review on acne due to hormonal changes and lifestyle. Indian J Nat Sci. 2020;10(59):18507–21.
[12] Kostecka M, Kostecka J, Szwed-Gułaga O, Jackowska I, Kostecka-Jarecka J. The impact of common acne on the wellbeing of young people aged 15-35 years and the influence of nutrition knowledge and diet on acne development. Nutrients. 2022;14(24):5293. DOI: 10.3390/nu14245293
[13] Bae IH, Kwak JH, Na CH, Kim MS, Shin BS, Choi H. A comprehensive review of the acne grading scale in 2023. Ann Dermatol. 2024;36(2):65–73. DOI: 10.5021/ad.23.094
[14] Alsulaimani H, Kokandi A, Khawandanh S, Hamad R. Severity of acne vulgaris: Comparison of two assessment methods. Clin Cosmet Investig Dermatol. 2020;13:711–6. DOI: 10.2147/ccid.s266320
[15] Kravvas G, Al-Niaimi F. A systematic review of treatments for acne scarring. Part 1: Non-energy-based techniques. Scars Burns Healing. 2017;3:2059513117695312. DOI: 10.1177/2059513117695312
[16] Donofrio L, Carruthers A, Hardas B, Murphy DK, Carruthers J, Jones D, et al. Development and validation of a photonumeric scale for evaluation of facial skin texture. Dermatol Surg. 2016;42:S219–S226. DOI: 10.1097/ dss.0000000000000852
[17] WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Participants (2013). [cited 2024 November 22]. Available from: https://www.wma.net/policies-post/wma-declaration-of-helsinki
[18] Ghosh A, Das K. Efficacy and safety of nadifloxacin and benzoyl peroxide versus adapalene and benzoyl peroxide in acne vulgaris: A randomized open-label phase IV clinical trial. J Pharmacol Pharmacother. 2018;9(1):27–31. DOI: 10.4103/jpp.JPP_20_18
[19] Tuchayi SM, Makrantonaki E, Ganceviciene R, Dessinioti C, Feldman SR, Zouboulis CC. Acne vulgaris. Nat Rev Dis Primers. 2015;1(1):15029. DOI: 10.1038/nrdp.2015.29
[20] Scheer VM, Jungeström MB, Lerm M, Serrander L, Kalén A. Topical benzoyl peroxide application on the shoulder reduces Propionibacterium acnes: A randomized study. J Shoulder Elbow Surg. 2018;27(6):957–61. DOI: 10.1016/j. jse.2018.02.038
[21] See JA, Goh CL, Hayashi N, Suh DH, Casintahan FA. Optimizing the use of topical retinoids in Asian acne patients. J Dermatol. 2018;45(5):522–28. DOI: 10.1111/1346-8138.14314
[22] Bharti S, Vadlamudi HC. A strategic review on the involvement of receptors, transcription factors and hormones in acne pathogenesis. J Recept Signal Transduct Res. 2021;41(2):105–16. DOI: 10.1080/10799893.2020.1805626
[23] Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Dermatology: How to manage acne vulgaris. Drugs Context. 2021;10:1–18. DOI: 10.7573/dic.2021-8-6
[24] Branisteanu DE, Toader MP, Porumb EA, Serban IL, Pinzariu AC, Branisteanu CI, et al. Adult female acne: Clinical and therapeutic particularities. Exp Ther Med. 2022;23(2):151. DOI: 10.3892/etm.2021.11074
[25] Jennings T, Duffy R, McLarney M, Renzi M, Heymann WR, Decker A, et al. Acne scarring – pathophysiology, diagnosis, prevention and education: Part I. J Am Acad Dermatol. 2024;90(6):1123–34. DOI: 10.1016/j.jaad.2022.04.021
[26] Sullivan JV, Myers S. Skin structure and function, wound healing and scarring. In: Rostam DF, Neil WB, Babak JM, Cugno S, editors. Plastic Surgery – Principles and Practice [Internet]. Amsterdam: Elsevier; 2022:1–14. [cited 2024 December 12]. DOI: 10.1016/B978-0-323-65381-7.00001-0
[27] Baldwin H, Webster G, Stein Gold L, Callender V, Cook-Bolden FE, Guenin E. 50 years of topical retinoids for acne: Evolution of treatment. Am J Clin Dermatol. 2021;22:315–27. DOI: 10.1007/s40257-021-00594-8
[28] Szczuraszek P, Szczuraszek H, Sałata P, Paluch M, Tomkiewicz M, Tomkiewicz J, et al. The role of the retinoids in topical treatment of skin diseases-the review of the literature. J Educ Health Sport. 2023;13(3):309–19. DOI: 10.12775/ JEHS.2023.13.03.040
[29] Harper JC, Baldwin H, Stein Gold L, Guenin E. Efficacy and tolerability of a novel Tretinoin 0.05% lotion for the oncedaily treatment of moderate or severe Acne vulgaris in adult females. J Drugs Dermatol. 2019;18(11):1147–54.
[30] Pariser D, Guenin E. Tretinoin 0.05% lotion for the once-daily treatment of moderate and severe acne vulgaris in females: Effect of age on efficacy and tolerability. J Drugs Dermatol. 2019;18(12):1218–25.
[31] Tyring SK, Kircik L, Pariser DM, Woolery-Lloyd HC, Harper JC, Bhatt V, et al. The effects of once-daily tretinoin 0.05% lotion on quality of life in patients with moderate-to-severe acne vulgaris. Am J Clin Dermatol. 2020;21:891–9. DOI: 10.1007/s40257-020-00559-3
[32] Han G, Armstrong AW, Desai SR, Guenin E. Novel tretinoin 0.05% lotion for the once-daily treatment of moderateto-severe acne vulgaris in an Asian population. J Drugs Dermatol. 2019;18(9):910-916.
[33] Matin T, Patel P, Goodman MB. Benzoyl Peroxide. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 November 25]. Available from: https://pubmed.ncbi.nlm.nih.gov/30725905/
[34] Dréno B, Bissonnette R, Gagné-Henley A, Barankin B, Lynde C, Chavda R, et al. Long-term effectiveness and safety of up to 48 weeks’ treatment with topical adapalene 0.3%/benzoyl peroxide 2.5% gel in the prevention and reduction of atrophic acne scars in moderate and severe facial acne. Am J Clin Dermatol. 2019;20:725–32. DOI: 10.1007/s40257019-00454-6
[35] Tanizaki H, Hayashi N, Abe M. Evaluation of the efficacy of maintenance therapy for acne vulgaris using adapalene 0.1%/benzoyl peroxide 2.5% gel and benzoyl peroxide 2.5% gel for 24 weeks and assessment of atrophic acne scars using three-dimensional image analysis. J Dermatol. 2023;50(12):1513–22. DOI: 10.1111/1346-8138.16942
[36] Dubey A, Amane H. Comparative clinical study of efficacy and safety of adapalene 0.1% gel versus benzoyl peroxide 2.5% gel for the treatment of acne vulgaris. Int J Basic Clin Pharmacol. 2019;8:2317–21. DOI: 10.18203/2319-2003.ijbcp20194279
[37] Amrutha MP, Bifi J, Anoop T, Ajayakumar S, Radhakrishnan K, Rajiv S. Topical 0.1% adapalene gel versus 0.1% adapalene and 2.5% benzoyl peroxide combination gel in the treatment of mild-to-moderate acne vulgaris: An openlabel randomized controlled pilot study. Indian J Drugs Dermatol. 2021;7(1):20–3. DOI: 10.4103/ijdd.ijdd_29_20
[38] Kosmoski G, Miller D, Coret C, Atillasoy E. A topical combination regimen of benzoyl peroxide and retinol moisturizer for mild to moderate acne. J Drugs Dermatol. 2022;21(12):1340–6. DOI: 10.36849/jdd.6845
[39] Lu J, Cong T, Wen X, Li X, Du D, He G, et al. Salicylic acid treats acne vulgaris by suppressing AMPK/SREBP 1 pathway in sebocytes. Exp Dermatol. 2019;28(7):786–94. DOI: 10.1111/exd.13934
[40] Dal Belo SE, Kanoun-Copy L, Lambert C, Cornillon C, Muller B, Jouni H, et al. Efficacy of a multitargeted, salicylic acid-based dermocosmetic cream compared to benzoyl peroxide 5% in acne vulgaris: Results from a randomized study. J Cosmet Dermatol. 2024;23(3):891–7. DOI: 10.1111/jocd.16052
[41] Ye D, Xue H, Huang S, He S, Li Y, Liu J, Wang Z, Zeng W. (2022). A prospective, randomized, split‐face study of concomitant administration of low‐dose oral isotretinoin with 30% salicylic acid chemical peeling for the treatment of acne vulgaris in Asian population. Int J Dermatol. 2022;61(6):698–706. DOI: 10.1111/ijd.16127
[42] Gardner KD. Cis-men’s perspectives on male birth control [dissertation on the internet]. Arizona, USA: Arizona State University; 2022. [cited 2024 December 25]. Available from: https://keep.lib.asu.edu/items/171559
[43] Otlewska A, Baran W, Batycka-Baran A. Adverse events related to topical drug treatments for acne vulgaris. Expert Opin Drug Saf. 2020;19(4):513–21. DOI: 10.1080/14740338.2020.1757646